Published in J Clin Invest on October 10, 2011
New Biomarkers in Heart- and Renal Failure (IM19 Register) | NCT02830464
FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP) (GAP) | NCT03489993
Fibroblast Growth Factor 23 in Chronic Respiratory Failure (EFIC-RES) | NCT05258370
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III. Am J Clin Nutr (2013) 2.66
FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest (2012) 2.41
Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol (2012) 2.22
Dietary phosphorus is associated with greater left ventricular mass. Kidney Int (2013) 2.19
Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study. BMJ (2013) 2.17
Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol (2012) 2.10
Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: rationale and design of the EARNEST study. Am Heart J (2013) 2.07
Fibroblast growth factor 23 and risk of incident stroke in community-living adults. Stroke (2015) 2.06
Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes. J Am Soc Nephrol (2013) 1.95
The osteocyte: an endocrine cell ... and more. Endocr Rev (2013) 1.84
Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int (2012) 1.82
Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int (2012) 1.82
The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol (2015) 1.82
Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol (2013) 1.78
Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol (2013) 1.78
Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation (2014) 1.73
Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int (2015) 1.73
Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int (2013) 1.66
Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol (2013) 1.66
Primary osteoblast-like cells from patients with end-stage kidney disease reflect gene expression, proliferation, and mineralization characteristics ex vivo. Kidney Int (2014) 1.65
FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest (2016) 1.57
Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol (2012) 1.48
Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis. Am J Nephrol (2015) 1.46
Phosphate control in end-stage renal disease: barriers and opportunities. Nephrol Dial Transplant (2013) 1.46
Association of fibroblast growth factor-23 with arterial stiffness in the Multi-Ethnic Study of Atherosclerosis. Nephrol Dial Transplant (2014) 1.44
Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus. Am J Nephrol (2015) 1.42
Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol (2012) 1.41
Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab (2015) 1.27
FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab (2013) 1.26
Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun (2012) 1.25
Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab (2012) 1.21
A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One (2012) 1.20
Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res (2013) 1.17
Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol (2014) 1.16
Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail (2014) 1.15
FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol (2013) 1.14
Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. PLoS One (2014) 1.13
Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol (2013) 1.12
Klotho and chronic kidney disease. Contrib Nephrol (2013) 1.11
Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol (2013) 1.10
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol (2012) 1.09
FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med (2014) 1.09
Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One (2013) 1.09
Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet (2013) 1.09
The emerging role of Klotho in clinical nephrology. Nephrol Dial Transplant (2012) 1.08
Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study. J Am Heart Assoc (2014) 1.07
Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin J Am Soc Nephrol (2014) 1.06
Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol (2013) 1.05
Phosphate is a vascular toxin. Pediatr Nephrol (2012) 1.05
Renal and extrarenal actions of Klotho. Semin Nephrol (2013) 1.04
Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens (2014) 1.03
Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. Am J Nephrol (2013) 1.03
Non-systemic drugs: a critical review. Curr Pharm Des (2012) 1.02
The role of FGF23 in CKD--with or without Klotho. Nat Rev Nephrol (2012) 1.02
Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. Clin J Am Soc Nephrol (2012) 1.02
FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol (2012) 1.01
Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens (2012) 1.01
Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr (2014) 1.00
Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int (2016) 1.00
FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone (2012) 0.99
Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD. J Am Soc Nephrol (2014) 0.99
CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol (2014) 0.99
Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy. J Am Soc Nephrol (2015) 0.99
Arterial stiffness, central pressures, and incident hospitalized heart failure in the chronic renal insufficiency cohort study. Circ Heart Fail (2014) 0.99
Effects of frequent hemodialysis on ventricular volumes and left ventricular remodeling. Clin J Am Soc Nephrol (2013) 0.98
Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis (2013) 0.98
A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res (2014) 0.98
FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab (2014) 0.97
Serum fibroblast growth factor-23 is associated with incident kidney disease. J Am Soc Nephrol (2014) 0.97
Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease. Int J Hypertens (2014) 0.97
Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD. J Am Soc Nephrol (2014) 0.96
Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Ther Adv Cardiovasc Dis (2013) 0.96
Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate. J Am Soc Nephrol (2014) 0.96
Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol (2012) 0.95
Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium. PLoS One (2014) 0.95
Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS One (2013) 0.95
Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort. BMC Nephrol (2012) 0.95
Serum parathyroid hormone and 25-hydroxyvitamin D concentrations and risk of incident heart failure: the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc (2014) 0.95
Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models. Bone Res (2014) 0.95
Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int (2016) 0.95
Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol (2012) 0.95
Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. PLoS One (2014) 0.94
Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC). BMC Nephrol (2013) 0.94
A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease. Kidney Int Suppl (2011) (2013) 0.94
Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS). Neurology (2014) 0.94
Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. PLoS One (2013) 0.93
Endocrine crosstalk between muscle and bone. Curr Osteoporos Rep (2014) 0.93
FGF23 production by osteocytes. Pediatr Nephrol (2012) 0.93
Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol (2013) 0.93
The effect of vitamin D status on risk factors for cardiovascular disease. Nat Rev Nephrol (2013) 0.92
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial. J Am Heart Assoc (2014) 0.92
Urine neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease and death in CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis (2014) 0.92
Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone. Am J Physiol Renal Physiol (2012) 0.92
Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. J Am Soc Nephrol (2015) 0.92
Heart rate variability is a predictor of mortality in chronic kidney disease: a report from the CRIC Study. Am J Nephrol (2013) 0.92
FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin J Am Soc Nephrol (2012) 0.92
Vitamin D and chronic kidney disease. Korean J Intern Med (2014) 0.91
Mineral (Mal)Adaptation to Kidney Disease-Young Investigator Award Address: American Society of Nephrology Kidney Week 2014. Clin J Am Soc Nephrol (2015) 0.91
Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant (2014) 0.91
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 49.19
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
Prevalence of chronic kidney disease in the United States. JAMA (2007) 38.98
Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med (1990) 17.52
Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature (1997) 13.77
A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell (1998) 13.56
Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol (2006) 10.71
Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev (2005) 9.62
Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature (2006) 9.40
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med (2003) 8.87
NFAT signaling: choreographing the social lives of cells. Cell (2002) 8.17
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
Fibroblast growth factors. Genome Biol (2001) 7.32
Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol (2003) 6.99
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A (2001) 6.70
Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem (2006) 6.50
Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A (2005) 6.16
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem (2006) 5.78
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol (2005) 5.76
Immunochemical analysis of myosin heavy chain during avian myogenesis in vivo and in vitro. J Cell Biol (1982) 5.52
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med (2008) 5.01
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol (2010) 4.59
The parathyroid is a target organ for FGF23 in rats. J Clin Invest (2007) 4.47
Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest (2005) 4.31
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J (1998) 4.14
The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J (2000) 4.09
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 3.73
Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int (1995) 3.70
The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J (2000) 3.64
FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays (2000) 3.31
Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A (2002) 3.27
High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant (2009) 3.08
Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int (2010) 3.04
Myosin isoenzyme redistribution in chronic heart overload. Nature (1979) 2.89
Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun (2004) 2.86
Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol (2009) 2.81
Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis (2009) 2.70
Transcription factor GATA-4 regulates cardiac muscle-specific expression of the alpha-myosin heavy-chain gene. Mol Cell Biol (1994) 2.63
Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol (2001) 2.60
Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res (2004) 2.52
Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology (2005) 2.46
Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta (1992) 2.41
Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest (1987) 2.37
"Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res (1998) 2.30
Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest (1990) 2.25
Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis (2005) 2.24
Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol (2010) 2.20
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab (2009) 2.12
Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int (2009) 2.09
The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nat Med (2005) 2.02
The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem (2003) 1.99
Control of cardiac myosin heavy chain gene expression. Microsc Res Tech (2000) 1.97
Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta (2007) 1.97
Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem (1997) 1.96
MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond) (2008) 1.95
Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol (2001) 1.83
Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol (2010) 1.78
Use of tibial length to quantify cardiac hypertrophy: application in the aging rat. Am J Physiol (1982) 1.72
Effect of hypophosphatemia on myocardial performance in man. N Engl J Med (1977) 1.70
Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res (2008) 1.70
Induction of the skeletal alpha-actin gene in alpha 1-adrenoceptor-mediated hypertrophy of rat cardiac myocytes. J Clin Invest (1987) 1.69
Control of cardiac gene expression by mechanical stress. Annu Rev Physiol (1993) 1.67
Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. Dev Biol (2007) 1.67
Control of cardiac growth and function by calcineurin signaling. J Biol Chem (2003) 1.66
Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol (2001) 1.58
The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry (2004) 1.57
The cytoskeleton and related proteins in the human failing heart. Heart Fail Rev (2000) 1.49
The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol (2008) 1.47
Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res (2003) 1.46
Calsarcin-2 deficiency increases exercise capacity in mice through calcineurin/NFAT activation. J Clin Invest (2008) 1.40
Protein kinase A, Ca2+/calmodulin-dependent kinase II, and calcineurin regulate the intracellular trafficking of myopodin between the Z-disc and the nucleus of cardiac myocytes. Mol Cell Biol (2007) 1.30
Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. Am J Med Sci (1999) 1.28
Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients. J Am Soc Nephrol (2004) 1.27
Promotion of importin alpha-mediated nuclear import by the phosphorylation-dependent binding of cargo protein to 14-3-3. J Cell Biol (2005) 1.23
Trophic effect of human pericardial fluid on adult cardiac myocytes. Differential role of fibroblast growth factor-2 and factors related to ventricular hypertrophy. Circ Res (1997) 1.12
Stimulus specific changes of energy metabolism in hypertrophied heart. J Mol Cell Cardiol (2009) 1.05
Comparative toxicity of allylamine and acrolein in cultured myocytes and fibroblasts from neonatal rat heart. Toxicology (1989) 1.04
Impact of renal transplantation on uremic cardiomyopathy. Transplantation (1995) 1.04
Basic fibroblast growth factor induces myocardial hypertrophy following acute infarction in rats. Exp Physiol (1998) 1.01
Reversible depression in myocardial performance in dogs with experimental phosphorus deficiency. J Clin Invest (1978) 0.95
Fibroblast growth factor 2 isoforms and cardiac hypertrophy. Cardiovasc Res (2004) 0.94
Cardiovascular abnormalities in patients with X-linked hypophosphatemia. J Clin Endocrinol Metab (1997) 0.92
Cardioprotective effect of calcineurin inhibition in an animal model of renal disease. Eur Heart J (2010) 0.91
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Prevalence of chronic kidney disease in the United States. JAMA (2007) 38.98
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med (2006) 32.81
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30
Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis (2008) 15.04
Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med (2012) 14.99
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem (2007) 13.80
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Major causes of death among men and women in China. N Engl J Med (2005) 11.80
Recommendations for chamber quantification. Eur J Echocardiogr (2006) 11.39
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med (2002) 10.52
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A (2008) 9.86
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Transient regenerative potential of the neonatal mouse heart. Science (2011) 9.02
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation (2007) 8.62
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48
Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med (2010) 8.28
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med (2007) 7.90
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Body mass index and risk for end-stage renal disease. Ann Intern Med (2006) 7.56
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA (2008) 7.50
The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell (2008) 7.26
Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation (2008) 7.11
Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell (2002) 7.10
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med (2003) 6.70
Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature (2012) 6.65
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55
Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem (2006) 6.50
A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol (2002) 6.48
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 6.41
Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24
Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A (2005) 6.16
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13
Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol (2007) 6.00
Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int (2008) 5.90
Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the american heart association. Hypertension (2013) 5.88
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol (2005) 5.76
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med (2013) 5.62
Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med (2009) 5.58
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet (2005) 5.53
A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell (2006) 5.51
Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res (2010) 5.47
The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med (2005) 5.45
Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int (2009) 5.28
Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2007) 5.26
Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest (2007) 5.17
Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol (2008) 5.09
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06
Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. Am J Kidney Dis (2007) 5.06
Prevalence of the metabolic syndrome and overweight among adults in China. Lancet (2005) 5.05
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med (2008) 5.01
APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med (2013) 5.00
The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98
Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol (2010) 4.97
Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J (2009) 4.90
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature (2012) 4.84
Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res (2011) 4.75
Mortality attributable to smoking in China. N Engl J Med (2009) 4.75
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74